<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17389</article-id><article-id pub-id-type="doi">10.15690/vramn17389</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>GASTROENTEROLOGY: CURRENT ISSUES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ВОПРОСЫ ГАСТРОЭНТЕРОЛОГИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Sarcopenia and Dinapenia in Patients with Ulcerative Colitis (Cross-Sectional Observational Study)</article-title><trans-title-group xml:lang="ru"><trans-title>Саркопения и динапения у больных язвенным колитом (кросс-секционное обсервационное исследование)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9252-9152</contrib-id><contrib-id contrib-id-type="spin">6103-6690</contrib-id><name-alternatives><name xml:lang="en"><surname>Bicbavova</surname><given-names>Galiya R.</given-names></name><name xml:lang="ru"><surname>Бикбавова</surname><given-names>Галия Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Associate Professor</p></bio><bio xml:lang="ru"><p>к.м.н., доцент </p></bio><email>galiya1976@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6581-7017</contrib-id><contrib-id contrib-id-type="spin">1961-4082</contrib-id><name-alternatives><name xml:lang="en"><surname>Livzan</surname><given-names>Maria A.</given-names></name><name xml:lang="ru"><surname>Ливзан</surname><given-names>Мария А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Corresponding Member of the RAS</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, член-корреспондент РАН </p></bio><email>mlivzan@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><contrib-id contrib-id-type="spin">4456-1297</contrib-id><name-alternatives><name xml:lang="en"><surname>Drapkina</surname><given-names>Oksana M.</given-names></name><name xml:lang="ru"><surname>Драпкина</surname><given-names>Оксана М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Academician of the RAS</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, академик РАН</p></bio><email>drapkina@bk.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4088-240X</contrib-id><contrib-id contrib-id-type="spin">1964-5202</contrib-id><name-alternatives><name xml:lang="en"><surname>Lisyutenko</surname><given-names>Natalia S.</given-names></name><name xml:lang="ru"><surname>Лисютенко</surname><given-names>Наталья С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Assistant of the Department</p></bio><bio xml:lang="ru"><p>к.м.н., ассистент кафедры</p></bio><email>n.labuzina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6308-4377</contrib-id><contrib-id contrib-id-type="spin">6833-4986</contrib-id><name-alternatives><name xml:lang="en"><surname>Romanyuk</surname><given-names>Alisa E.</given-names></name><name xml:lang="ru"><surname>Романюк</surname><given-names>Алиса Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Student</p></bio><bio xml:lang="ru"><p>студентка лечебного факультета </p></bio><email>romalisa00@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Omsk State Medical University</institution></aff><aff><institution xml:lang="ru">Омский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Medical Research Center for Therapy and Preventive Medicine</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр терапии и профилактической медицины</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-06-11" publication-format="electronic"><day>11</day><month>06</month><year>2024</year></pub-date><volume>79</volume><issue>2</issue><issue-title xml:lang="ru"/><fpage>112</fpage><lpage>122</lpage><history><date date-type="received" iso-8601-date="2023-10-10"><day>10</day><month>10</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2024-03-21"><day>21</day><month>03</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Издательство "Педиатръ"</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2024-12-11"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnikramn.spr-journal.ru/jour/about/submissions</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/17389">https://vestnikramn.spr-journal.ru/jour/article/view/17389</self-uri><abstract xml:lang="en"><p><bold>Background. </bold>Sarcopenia is a generalised, progressive decline in skeletal muscle mass, strength and performance leading to reduced quality of life, increased risk of falls, hospitalisation and mortality. Primary sarcopenia results from age-related changes in muscle tissue. In certain cases, sarcopenia develops secondary as a consequence of diseases including ulcerative colitis (UC), which is associated with a systemic inflammatory process, malabsorption syndrome, restriction of patients’ physical activity and nutrient deficiencies. The term “dynapenia” or “probable sarcopenia” has been proposed to describe the decrease in muscle strength. Studies have demonstrated that muscle strength is a more relevant marker for predicting adverse outcomes because its measurement is more practical, whereas muscle mass is technically difficult to measure.</p> <p><bold>Aims</bold> — to increase the effectiveness of the diagnosis of dinapenia, to assess the prevalence and risk factors of its formation in patients with UC.</p> <p><bold>Methods.</bold> A single-centre, observational cross-sectional study included 80 UC patients. To identify factors associated with the development of dinapenia, patients with dinapenia were compared with patients without dinapenia. The investigated parameters in patients: sex, age, body mass index, peculiarities of the course of the disease, ongoing treatment, concomitant pathology, peculiarities of nutrition, nutritional deficiency, malabsorption syndrome, bad habits, psychological stress and sleep duration, physical activity, laboratory indicators of inflammation, myokine-adipokine profile. Statistical parameters were calculated using Statistica 10.0.1011.0 programme.</p> <p><bold>Results.</bold> Dinapenia is present in 32.5% of UC patients. Risk factors for the formation of dinapenia in UC patients include female sex (p = 0.0003); nutritional insufficiency (p = 0.021); low physical activity (p = 0.010); artificial feeding in infancy (p = 0.024); inflammation, namely C-reactive protein, autoantibodies of class G against double-stranded DNA (p = 0.006; p = 0.002 respectively). Patients with UC with dinapenia significantly more often gave a positive answer to the questionnaire question “Does daily activity cause you a lot of stress?” (p = 0.048). In the group of UC patients with dinapenia, the level of cortisol in evening saliva was significantly higher than in the comparison group (p = 0.005).</p> <p><bold>Conclusions. </bold>Sarcopenia and UC are multifactorial conditions with common developmental mechanisms that can burden each other. Dynamometry is not technically difficult and is justified from an economic point of view. The timely detection of dinapenia and its correction will additionally affect the mechanisms of UC pathogenesis in order to improve the quality of life and prognosis of patients.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Саркопения — это генерализованное, прогрессирующее снижение массы скелетных мышц, силы и работоспособности, ведущее к снижению качества жизни, повышенному риску падений, госпитализации и смертности. Первичная саркопения является следствием возрастных изменений мышечной ткани. В определенных случаях саркопения развивается вторично, как следствие заболеваний, в числе которых язвенный колит (ЯК), что связано с системным воспалительным процессом, синдромом мальабсорбции, ограничением физической активности пациентов и дефицитом нутриентов. Для обозначения снижения мышечной силы предложено использовать термин «динапения» или «вероятная саркопения». Исследования продемонстрировали, что мышечная сила является более значимым маркером в отношении прогнозирования неблагоприятных исходов, поскольку ее измерение более применимо с практической точки зрения, в то время как измерять мышечную массу технически сложно.</p> <p><bold>Цель исследования</bold> — для повышения эффективности диагностики динапении оценить распространенность и факторы риска ее формирования у больных ЯК.</p> <p><bold>Методы.</bold> В одноцентровое, обсервационное кросс-секционное исследование включено 80 больных ЯК. Для выявления факторов, ассоциированных с развитием динапении, пациенты с динапенией были сопоставлены с пациентами без динапении. Исследуемые параметры у больных: пол, возраст, индекс массы тела, особенности течения заболевания, проводимое лечение, сопутствующая патология, особенности питания, нутритивная недостаточность, синдром мальабсорбции, вредные привычки, психологический стресс и продолжительность сна, физическая активность, лабораторные показатели воспаления, миокино-адипокиновый профиль. Статистические показатели вычислены при помощи программы Statistica 10.0.1011.0.</p> <p><bold>Результаты.</bold> Динапения присутствует у 32,5% больных ЯК. К факторам риска формирования динапении у больных ЯК относятся женский пол (р = 0,0003), нутритивная недостаточность (р = 0,021), низкая физическая активность (р = 0,010), искусственное вскармливание в младенчестве (р = 0,024), воспаление, а именно С-реактивный белок, аутоантитела класса G против двуспиральной ДНК (р = 0,006; р = 0,002 соответственно). Больные ЯК с динапенией значимо чаще давали положительный ответ на вопрос анкеты «Вызывает ли повседневная деятельность у Вас большое напряжение?» (р = 0,048). В группе больных ЯК с динапенией уровень кортизола в вечерней слюне был значимо выше, чем в группе сравнения (р = 0,005).</p> <p><bold>Заключение. </bold>Динапения и ЯК являются многофакторными состояниями с общими механизмами развития, которые способны отягощать течение друг друга. Проведение динамометрии не представляет технической сложности и оправдано с экономической точки зрения. Своевременно выявленная динапения и ее коррекция позволят дополнительно воздействовать на механизмы патогенеза ЯК с целью улучшения качества жизни и прогноза пациентов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>sarcopenia</kwd><kwd>ulcerative colitis</kwd><kwd>dinapenia</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>саркопения</kwd><kwd>язвенный колит</kwd><kwd>динапения</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Исследование выполнено за счет гранта Российского научного фонда (проект № 23-25-10035, https://rscf.ru/project/23-25-10035/)</institution></institution-wrap></funding-source></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi: https://doi.org/10.1093/ageing/afy169</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547–558. doi: https://doi.org/10.1093/gerona/glu010</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Chumlea WMC, Cesari M, Evans WJ, et al. International working group on Sarcopenia. The Journal of Nutrition, Health &amp; Aging. 2011;15:450–455. doi: https://doi.org/10.1007/s12603-011-0092-7</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Seene T, Kaasik P. Muscle weakness in the elderly: role of sarcopenia, dynapenia, and possibilities for rehabilitation. Eur Rev Aging Phys Act. 2012;9(2):109–117. doi: https://doi.org/10.1007/s11556-012-0102-8</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Schaap LA, van Schoor NM, Lips P, Visser M. Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam. J Gerontol A Biol Sci Med Sci. 2018;73(9): 1199–1204. doi: https://doi.org/10.1093/gerona/glx245</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ibrahim K, May C, Patel HP, et al. A feasibility study of implementing grip strength measurement into routine hospital practice (GRImP): study protocol. Pilot Feasibility Stud. 2016;2:27. doi: https://doi.org/10.1186/s40814-016-0067-x</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015;386(9990):266–273. doi: https://doi.org/10.1016/S0140-6736(14)62000-6</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Nishikawa H, Nakamura S, Miyazaki T., et al. Inflammatory bowel disease and sarcopenia: its mechanism and clinical importance. J Clin Med. 2021;10(18):4214. doi: https://doi.org/10.3390/jcm10184214</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ryan E, McNicholas D, Creavin B, et al. Sarcopenia and inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2019;25(1):67–73. doi: https://doi.org/10.1093/ibd/izy212</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. doi: https://doi.org/10.1038/ajg.2015.233</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi: https://doi.org/10.1053/j.gastro.2020.12.031</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ge X, Jiang L, Yu W, et al. The importance of sarcopenia as a prognostic predictor of the clinical course in acute severe ulcerative colitis patients. Dig Liver Dis. 2021;53(8):965–971. doi: https://doi.org/10.1016/j.dld.2021.03.031</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Pedersen M, Cromwell J, Nau P. Sarcopenia is a predictor of surgical morbidity in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(10):1867–1872. doi: https://doi.org/10.1097/MIB.0000000000001166</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Cushing KC, Kordbacheh H, Gee MS, et al. Sarcopenia is a novel predictor of the need for rescue therapy in hospitalized ulcerative colitis patients. J Crohns Colitis. 2018;12(9):1036–1041. doi: https://doi.org/10.1093/ecco-jcc/jjy064</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ивашкин В.Т., Шелыгин Ю.А., Белоусова Е.А., и др. Проект клинических рекомендаций по диагностике и лечению язвенного колита // Колопроктология. — 2019. — Т. 18. — № 4. — С. 7–36. [Ivashkin VT, Shelygin YuA, Belousova EA, et al. Project: Clinical guidelines for the diagnostics and treatment of ulcerative colitis. Koloproktologiya. 2019;18(4):7–36. (In Russ.)] doi: https://doi.org/10.33878/2073-7556-2019-18-4-7-36</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>CINDI dietary guide. Document EUR/00/5018028, E70041R. Copenhagen, WHO Regional Office for Europe; 2003. 42 p.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Haskey N, Peña-Sánchez JN, Jones JL, et al. Development of a screening tool to detect nutrition risk in patients with inflammatory bowel disease. Asia Pac J Clin Nutr. 2018;27(4):756–762. doi: https://doi.org/10.6133/apjcn.112017.01</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Fiorindi C, Dragoni G, Scaringi S, et al. Relationship between nutritional screening tools and GLIM in complicated IBD requiring surgery. Nutrients. 2021;13(11):3899. doi: https://doi.org/10.3390/nu13113899</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Ерофеев Ю.В., Болдырева М.С., Турчанинов Д.В. Организация и методика проведения социологических исследований здоровья сельского населения для информационного обеспечения системы социально-гигиенического мониторинга. Методические рекомендации. — Омск: Изд-во ФГУ ЦГСЭН Омской области, 2004. — 52 с. [Erofeev YuV, Boldyreva MS, Turchaninov DV. Organizatsiya i metodika provedeniya sotsiologicheskikh issledovanii zdorov’ya sel’skogo naseleniya dlya informatsionnogo obespecheniya sistemy sotsial’no-gigienicheskogo monitoringa. Metodicheskie rekomendatsii. Omsk: Izdatel’stvo FGU TsGSEN Omskoi oblasti; 2004. 52 s. (In Russ.)]</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Reeder LG, Chapman JM, Coulson AH. Socioenvironmental stress, tranquilizers and cardiovascular disease. Proceedings of the Excerpta Medica International Congress Series. 1968;182:226–238</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Rom O, Kaisari S, Aizenbud D, Reznick AZ. Lifestyle and sarcopenia-etiology, prevention, and treatment. Rambam Maimonides Med J. 2012;3(4):e0024. doi: https://doi.org/10.5041/RMMJ.10091</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Dhaliwal A, Quinlan JI, Overthrow K, et al. Sarcopenia in inflammatory bowel disease: a narrative overview. Nutrients. 2021;13(2):656. doi: https://doi.org/10.3390/nu13020656</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Yuan S, Larsson SC. Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism. 2023;144:155533. doi: https://doi.org/10.1016/j.metabol.2023.155533</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Mawdsley JE, Rampton DS. Psychological stress in IBD: New insights into pathogenic and therapeutic implications. Gut. 2005;54(10):1481–1491. doi: https://doi.org/10.1136/gut.2005.064261</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Vanuytsel T, van Wanrooy S, Vanheel H, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut. 2014;63(8):1293–1299. doi: https://doi.org/10.1136/gutjnl-2013-305690</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Miller R, Wojtyniak JG, Weckesser LJ, et al. How to disentangle psychobiological stress reactivity and recovery: a comparison of model-based and non-compartmental analyses of cortisol concentrations. Psychoneuroendocrinology. 2018;90:194–210. doi: https://doi.org/10.1016/j.psyneuen.2017.12.019</mixed-citation></ref></ref-list></back></article>
